factsheet

  • Sales Revenues: US$ 1.03 billion, INR 56.10 billion (FY 2012-13)
  • Operating Profit (EBIDTA): US$ 384 million, INR 20.91 billion (FY 2012-13)
  • US Sales: US$ 531 million (FY 2012-13)
  • UK Sales: GBP 108 million (FY 2012-13)
  • Products launched globally:75 (April - September 2013)
  • Patents filed: 1,733 (till September 2013)
  • Patents granted: 228 (till September 2013)
  • International Offices:  USA, UK, Ireland, France
  • Wockhardt has 3 research centres globally with over 607 scientists of which over 80 are doctorates. Its multi-disciplinary research activities encompass pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery system, new drug discovery programme and process engineering for Active Pharmaceutical Ingredients.
  • Wockhardt's 12 manufacturing plants are located in India, UK, Ireland, US, and are compliant to international regulatory standards including US FDA and UK MHRA. These manufacturing plants are multi-technology and can manufacture all the dosage forms including sterile products as well as products with lyophilised dosage forms.
  • Wockhardt is the 4th company in the world to have developed recombinant insulin, Wosulin - from concept to market stage. It also developed a patented delivery device ‘Pen’ for Wosulin injections.
  • First Company in the world, after the originator, to have developed and marketed a long acting insulin analogue, glargine (Glaritus).
  • Wockhardt was four times in a row, awarded the prestigious Patent Award by the Government of India, for the ‘Maximum number of Patent Filings and Grants from India’.
  • Wockhardt has also received the prestigious Worldstar award in the field of packaging, this being the highest recognition in the world of packaging.
  • Wockhardt UK is the largest Indian Generics Company in the United Kingdom.
  • Wockhardt's Pinewood is the No.1 branded generics company in Ireland.
  • Wockhardt was ranked 76th amongst the World’s Top 100 Pharmaceutical Companies and only the 4th Indian Pharmaceutical Company in this elite 100 group (Scrip 100, 2011 edition).
  • Wockhardt has been a 'Business Superbrand' for two consecutive years - the only pharmaceutical & healthcare company in India to get this rare distinction.
  • Wockhardt’s CSR (Corporate Social Responsibility) arm under Wockhardt Foundation has touched in a short period of time, 3 million lives through its various medical and social programmes and initiatives.
  • Wockhardt Hospitals is associated with Partners Harvard Medical International, an international arm of Harvard Medical School, USA.
  • Wockhardt is amongst Top-5 in the field of Healthcare in India.

 Top